Deals channel feed – Endpoints News

Deals channel feed

The disruptors at EQRx have their eyes on the PD-(L)1 market — teeing up $150M cash to grab 2 backbone therapies from China

5 years ago

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

5 years ago

Bayer buys a biotech ‘race horse’ with a $4B deal — $2B in cash — aimed at going big into gene therapy

5 years ago

Ultragenyx injects $40M to grab Solid's microdystrophin transgene — while sidestepping the AAV9 vector that stirred up safety fears

5 years ago

Retrophin beefs up the rare disease drug pipeline with a $517M buyout deal

5 years ago

Pfizer scoops up an antibiotic in rare M&A deal, bagging a virtual startup operating on a shoestring budget

5 years ago

Exclusive: Eyeing big Covid-19 testing expansion, Ginkgo rolls out 50M rapid antigen diagnostics

5 years ago

Roche wades deeper into Covid-19 fight, inking antiviral pact with $350M cash following Regeneron deal

5 years ago

Master dealmaker David Hung retools a SPAC sedan into a financing muscle vehicle that leaves his cancer startup with $850M and a place on Wall Street

5 years ago

Here's how Bristol Myers' CEO Giovanni Caforio completed a $13B buyout: He moved fast, upped the bid quickly and demanded everyone to keep up

5 years ago

Cara lines up a $440M deal for US rights to its late-stage drug for severe itch, with $150M cash on the table

5 years ago

Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics

5 years ago

Endo pays $658M in a further bet on collagen-based medicines, buying out longtime biopharma partner

5 years ago

Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip

5 years ago

Eli Lilly bags an early-stage biotech for the neuro team — paying $135M cash and offering $1B-plus in milestones

5 years ago

Astellas wagers $425M-plus to buy a shot at hatching a 'neural dust' breakthrough in bioelectronics

5 years ago

Roche turns to a Harvard upstart out of George Church’s lab to construct AAV 2.0 model vectors — a key part of building the gene therapy pipeline

5 years ago

A major new investor just arrived at the biotech party, as Evotec nets $295M from Mubadala and Novo

5 years ago

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

5 years ago

Roche joins AbbVie in stepping on Vertex's turf, betting $96M on an alternative CF approach

5 years ago

Occupied with immunology and cancer, Merck KGaA hands off osteoarthritis drug to Novartis for €50M cash

5 years ago

Neil Kumar bets nearly $1B on what BridgeBio hopes will be their first big drug

5 years ago

Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout

5 years ago

Roche shells out $200M for rights to Vaccibody's neoantigen cancer vaccine

5 years ago

First page Previous page 84 85 868788 89 90 Next page Last page